407 related articles for article (PubMed ID: 33488631)
1. Allogeneic CAR Cell Therapy-More Than a Pipe Dream.
Caldwell KJ; Gottschalk S; Talleur AC
Front Immunol; 2020; 11():618427. PubMed ID: 33488631
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
3. [Development of allogeneic CAR T-cells].
Alcazer V; Depil S
Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
Martínez Bedoya D; Dutoit V; Migliorini D
Front Immunol; 2021; 12():640082. PubMed ID: 33746981
[TBL] [Abstract][Full Text] [Related]
5. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies.
Dhakal B; Chhabra S; Savani BN; Hamadani M
Br J Haematol; 2022 Apr; 197(1):28-40. PubMed ID: 34671973
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacology Considerations for the "Off-the-Shelf" Allogeneic Cell Therapies.
Mody H; Sutaria DS; Miles D
Clin Pharmacol Ther; 2024 Jun; 115(6):1233-1250. PubMed ID: 38501153
[TBL] [Abstract][Full Text] [Related]
8. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
Front Immunol; 2020; 11():586168. PubMed ID: 33584651
[TBL] [Abstract][Full Text] [Related]
9. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
Moradi V; Omidkhoda A; Ahmadbeigi N
Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
[TBL] [Abstract][Full Text] [Related]
10. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O
Front Immunol; 2021; 12():780145. PubMed ID: 34975869
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
13. "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
An Y; Jin X; Zhang H; Zhang M; Mahara S; Lu W; Zhao M
Curr Treat Options Oncol; 2023 May; 24(5):409-441. PubMed ID: 37010679
[TBL] [Abstract][Full Text] [Related]
14. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
15. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
[TBL] [Abstract][Full Text] [Related]
16. Off the shelf T cell therapies for hematologic malignancies.
McCreedy BJ; Senyukov VV; Nguyen KT
Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
[TBL] [Abstract][Full Text] [Related]
17. Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
Michaux A; Mauën S; Breman E; Dheur MS; Twyffels L; Saerens L; Jacques-Hespel C; Gauthy E; Agaugué S; Gilham DE; Sotiropoulou PA
J Immunother; 2022 Apr; 45(3):150-161. PubMed ID: 35191428
[TBL] [Abstract][Full Text] [Related]
18. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L
Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295
[TBL] [Abstract][Full Text] [Related]
19. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
Kagoya Y; Guo T; Yeung B; Saso K; Anczurowski M; Wang CH; Murata K; Sugata K; Saijo H; Matsunaga Y; Ohashi Y; Butler MO; Hirano N
Cancer Immunol Res; 2020 Jul; 8(7):926-936. PubMed ID: 32321775
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.
Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S; Mackall CL; Negrin RS
Clin Cancer Res; 2021 Nov; 27(21):6054-6064. PubMed ID: 34376537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
